Evommune, Inc.
No SEC Form 4 filings for $EVMN in the last 30 days.
See all $EVMN insider activity →Analysts initiated coverage on several companies: Needham rated Evommune (EVMN) Buy with a $28 target, Daiwa rated ACM Research (ACMR) Buy with a $136 target, Wolfe Research rated Harmony Biosciences (HRMY) Outperform with a $60 target, RBC rated Atlassian (TEAM) Outperform with a $215 target, and RBC rated JFrog (FROG) Outperform with a $118 target.
Evommune, Inc. (EVMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights ‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in
Carver Kyle (Chief Financial Officer) purchased 1,000 shares of Evommune, Inc. (EVMN) at $13.26 on 2026-07-08.
Over the past 7 days, alphai's AI scored 1 news story mentioning EVMN (Evommune, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent EVMN coverage spans insider activity, financial news and earnings.
New coverage may attract investors and lift price toward target.
Near-term catalyst is September 2026 AD Phase 2b top-line data for EVO756; longer-dated catalysts include migraine Phase 2b top-line in 2027 and EVO301 Phase 2a conference presentation.
This is a small insider buy with limited standalone signal, but it can modestly support near-term sentiment if traders treat it as confidence.
Director buy while the stock trades near its 52-week low is a contrarian sentiment signal.
A director open-market buy can be a modest bullish signal, but the filing provides no new company fundamentals or guidance.
alphai scores every news story that mentions EVMN with an AI model for sentiment and relevance, and aggregates insider trades from Evommune, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts initiated coverage on several companies: Needham rated Evommune (EVMN) Buy with a $28 target, Daiwa rated ACM Research (ACMR) Buy with a $136 target, Wolfe Research rated Harmony Biosciences (HRMY) Outperform with a $60 target, RBC rated Atlassian (TEAM) Outperform with a $215 target, and RBC rated JFrog (FROG) Outperform with a $118 target.
2 min readEvommune, Inc. (EVMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights ‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in
4 min readCarver Kyle (Chief Financial Officer) purchased 1,000 shares of Evommune, Inc. (EVMN) at $13.26 on 2026-07-08.
1 min readA roundup of July 8, 2026 insider trades reported major buys in Mission Produce (AVO), where Globalharvest Holdings Venture Ltd bought 650,415 shares for about $8.28M at $12.73 avg, and Boundless Bio (BOLD), where Tang Capital bought 57,210 shares for about $141.9K. Major sells included Rocket Lab (RKLB) CEO Peter Beck selling about $286.4M and Dell (DELL) director Egon Durban/Silver Lake selling about $29.9M.
7 min readKIRSCH ARTHUR S purchased 10,000 indirectly-held shares of Evommune, Inc. (EVMN) at $13.30 ($0.13M total) on 2026-07-07.
2 min readLevi & Korsinsky said it is investigating Evommune, Inc. (NYSE: EVMN) after its lead drug EVO756 failed a Phase 2b primary endpoint, which the company said led to about a 38% share drop. The firm cites CEO Luis Pena and CSO Jeegar Patel sales/exercises on June 22, 2026 under Rule 10b5-1 plans before the disclosure.
5 min readA roundup of analysts’ June 30 price-target changes across many stocks. Examples: Wells Fargo raised AAL to $17 from $12; Leerink raised ABVX to $148 from $140; JPMorgan cut ACI to $20 from $22; Jefferies cut ALB to $211 from $244; Goldman cut APA to $32 from $34; KeyCorp raised ATI to $211 from $175.
2 min readCohen David E sold 600 shares of Evommune, Inc. (EVMN) at $21.38 on 2026-06-02 under a Rule 10b5-1 trading plan.
2 min readCohen David E sold 5,456 shares of Evommune, Inc. (EVMN) at $20.21 ($0.11M total) on 2026-06-02 under a Rule 10b5-1 trading plan.
2 min readPatel Jeegar Pravinkumar (Chief Scientific Officer) sold 16,687 shares of Evommune, Inc. (EVMN) at $22.74 ($0.38M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
3 min read
